Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Latanoprost (ausschließlich EDO 30x0,3 ml sowie 90x0,3ml), ATC S01EE01 für die Zeit 01.12.2026 - 30.11.2028

Section 130a (8) SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Latanoprost (exclusively EDO 30x0.3 ml and 90x0.3 ml), ATC S01EE01, DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until new medicine discount contracts come into force. A discount contract under the approval model for the aforementioned active substance comes into force for the first time on 01.12.2026 and ends on 30.11.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.